Axial spondyloarthritis Market: Epidemiology, Therapies, Companies, DelveInsight | UCB, AbbVie, Pfizer, Amgen, Janssen Biotech, Pozen, Iroko Pharmaceuticals, Syntex Pharmaceuticals, Horizon Pharma, Eli Lilly and Company, Kyowa Kirin, AbbVie, Celgene, Inma

Axial spondyloarthritis therapies, such as SIMPONI (golimumab), XELJANZ (tofacitinib), CIMZIA (certolizumab pegol), ENBREL (Etanercept), RINVOQ (Upadacitinib), COSENTYX (secukinumab), TALTZ (Ixekizumab), LUMICEF (brodalumab), BIMZELX (bimekizumab), and others, are expected to boost the Axial spondyloarthritis Market in the upcoming years.

DelveInsight has launched a new report on "Axial spondyloarthritis - Market Insights, Epidemiology, and Market Forecast-2034" that delivers an in-depth understanding of the Axial spondyloarthritis, historical and forecasted epidemiology as well as the Axial spondyloarthritis market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

Discover about the Axial spondyloarthritis market report @ https://www.delveinsight.com/report-store/axial-spondyloarthritis-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Some of the key facts of the Axial spondyloarthritis Market Report:

The axial spondyloarthritis (axSpA) market is projected to grow at a strong compound annual growth rate (CAGR) over the study period from 2020 to 2034. AxSpA is a complex inflammatory disease primarily affecting the sacroiliac joints and spine, leading to bone erosion and abnormal bone formation, which can eventually result in ankylosis.
Its development is influenced by genetic, immunological, mechanical, and environmental factors. Among genetic contributors, HLA-B27 is the most significant, although other genes such as ERAP1 and those encoding interleukins (IL-23, IL-12, IL-17) are also implicated. Importantly, the condition can still occur in the absence of HLA-B27.
AxSpA is classified into two forms: non-radiographic axial spondyloarthritis (nr-axSpA) and radiographic axial spondyloarthritis (r-axSpA), the latter also known as ankylosing spondylitis (AS).
According to DelveInsight, there were approximately 4.58 million prevalent cases of axSpA in the 7MM in 2023, and this number is expected to rise significantly through 2034. The United States represents the largest share of the axSpA market, followed by countries in the EU4, the UK, and Japan. Japan alone accounted for roughly 21,300 cases in 2023.
Among the genes linked to axSpA, HLA-B27 is associated with a higher prevalence of diagnosed AS cases compared to other genetic markers such as ERAP1 and interleukin-related genes.
Meanwhile, ENBREL (Immunex/Amgen), XELJANZ (Pfizer), and SIMPONI (Johnson & Johnson) are approved only for AS. In Japan, LUMICEF is approved for both axSpA subtypes.
Recent approvals include BIMZELX (bimekizumab), which received authorization from Japan's Ministry of Health in December 2023 and from the European Commission in June 2023 for treating adults with active nr-axSpA and AS unresponsive to standard therapies.
Although multiple therapies are available to manage symptoms and slow disease progression, no cure currently exists, and the pipeline for new axSpA treatments remains limited.
According to DelveInsight's estimates, approximately 569,000 individuals in the United States were diagnosed with non-radiographic axial spondyloarthritis in 2023.
In September 2024, the FDA approved Bimzelx, UCB's dual IL‐17A/IL‐17F-inhibiting biologic, for treating active ankylosing spondylitis (AS) and non-radiographic axial spondyloarthritis (nr‐axSpA) in adults. It's the first therapy to address the entire spectrum of axSpA and represents a significant addition to treatment options.
In February 2024, the FDA accepted UCB's supplemental biologics license application (sBLA) for Bimzelx, expanding its approved indications to include active AS, nr‐axSpA, and psoriatic arthritis (PsA).
Key Axial spondyloarthritis companies such as UCB, AbbVie, Pfizer, Amgen, Janssen Biotech, Pozen, Iroko Pharmaceuticals, Syntex Pharmaceuticals, Horizon Pharma, Eli Lilly and Company, Kyowa Kirin, AbbVie, Celgene, Inmagene Biopharmaceuticals, and others are evaluating new drugs for Axial spondyloarthritis to improve the treatment landscape.
Promising Axial spondyloarthritis therapies include SIMPONI (golimumab), XELJANZ (tofacitinib), CIMZIA (certolizumab pegol), ENBREL (Etanercept), RINVOQ (Upadacitinib), COSENTYX (secukinumab), TALTZ (Ixekizumab), LUMICEF (brodalumab), BIMZELX (bimekizumab), and others.

Axial Spondyloarthritis Overview

Axial spondyloarthritis (AxSpA) is a form of arthritis that primarily affects the spine and sacroiliac joints, the joints connecting the base of the spine to the pelvis, causing pain and inflammation. It can also involve other joints and organs, making it a systemic condition. AxSpA often has a hereditary component and is classified into two types: ankylosing spondylitis (radiographic axSpA), where joint damage is visible on X-rays, and non-radiographic axSpA, where changes may only be detected using MRI. The disease typically develops between the ages of 20 and 40, and while ankylosing spondylitis is more common in men, non-radiographic AxSpA tends to affect men and women at similar rates.

The axial spondyloarthritis report offers a comprehensive overview of the disease's underlying mechanisms, diagnostic methods, and treatment pathways. It also provides insights into the real-world patient journey-from the onset of symptoms and time to diagnosis, through to treatment initiation and ongoing management.


Axial Spondyloarthritis Market Outlook

The axial spondyloarthritis market across the seven major markets is projected to experience significant growth starting in 2024.

Among these markets, the United States holds the largest share, followed by the EU4 (Germany, Spain, Italy, and France), the United Kingdom, and Japan. Within the EU4 and the UK, Germany leads in market size, trailed by Spain, while France represents the smallest market.

In 2023, the overall market value for axial spondyloarthritis treatments was approximately USD 9 million, with conventional therapies accounting for the majority of this share.

Discover how the Axial spondyloarthritis market is rising in the coming years @ https://www.delveinsight.com/sample-request/axial-spondyloarthritis-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Axial Spondyloarthritis Marketed Drugs
SIMPONI (golimumab): Janssen Pharmaceuticals
XELJANZ (tofacitinib): Pfizer

Scope of the Axial Spondyloarthritis Market Report
Study Period: 2020-2034
Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
Key Axial spondyloarthritis Companies: UCB, AbbVie, Pfizer, Amgen, Janssen Biotech, Pozen, Iroko Pharmaceuticals, Syntex Pharmaceuticals, Horizon Pharma, Eli Lilly and Company, Kyowa Kirin, AbbVie, Celgene, Inmagene Biopharmaceuticals, and others
Axial spondyloarthritis Therapies: SIMPONI (golimumab), XELJANZ (tofacitinib), CIMZIA (certolizumab pegol), ENBREL (Etanercept), RINVOQ (Upadacitinib), COSENTYX (secukinumab), TALTZ (Ixekizumab), LUMICEF (brodalumab), BIMZELX (bimekizumab), and others.
Axial spondyloarthritis Therapeutic Assessment: Axial spondyloarthritis current marketed and Axial spondyloarthritis emerging therapies
Axial spondyloarthritis Market Dynamics: Axial spondyloarthritis market drivers and Axial spondyloarthritis market barriers
Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies
Axial spondyloarthritis Unmet Needs, KOL's views, Analyst's views, Axial spondyloarthritis Market Access and Reimbursement

To know what's more in our Axial spondyloarthritis report, visit https://www.delveinsight.com/report-store/axial-spondyloarthritis-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Key benefits of the Axial Spondyloarthritis Market Report:
Axial spondyloarthritis market report covers a descriptive overview and comprehensive insight of the Axial spondyloarthritis Epidemiology and Axial spondyloarthritis market in the 7MM (the United States, EU5 (Germany, Spain, France, Italy, UK) & Japan).
The Axial spondyloarthritis market report provides insights into the current and emerging therapies.
The Axial spondyloarthritis market report provides a global historical and forecasted market covering drug outreach in 7MM.
The Axial spondyloarthritis market report offers an edge that will help in developing business strategies by understanding trends shaping and driving the Axial spondyloarthritis market.

Got queries? Click here to know more about the Axial spondyloarthritis market Landscape https://www.delveinsight.com/sample-request/axial-spondyloarthritis-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Table of Contents

1. Report Introduction
2. Executive Summary
3. SWOT analysis
4. Axial Spondyloarthritis Patient Share (%) Overview at a Glance
5. Axial Spondyloarthritis Market Overview at a Glance
6. Axial Spondyloarthritis Disease Background and Overview
7. Axial Spondyloarthritis Epidemiology and Patient Population
8. Country-Specific Patient Population of Axial Spondyloarthritis
9. Axial Spondyloarthritis Current Treatment and Medical Practices
10. Unmet Needs
11. Axial Spondyloarthritis Emerging Therapies
12. Axial Spondyloarthritis Market Outlook
13. Country-Wise Axial Spondyloarthritis Market Analysis (2020-2034)
14. Market Access and Reimbursement of Therapies
15. Market drivers
16. Market barriers
17. Appendix
18. Axial Spondyloarthritis Report Methodology
19. DelveInsight Capabilities
20. Disclaimer
21. About DelveInsight

Click here to read more about Axial spondyloarthritis Market Outlook 2034 https://www.delveinsight.com/report-store/axial-spondyloarthritis-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Related Reports:

Axial Spondyloarthritis Pipeline Insights, DelveInsight

"Axial spondyloarthritis Pipeline Insight, 2024" report by DelveInsight outlines comprehensive insights of present clinical development scenarios and growth prospects across the Axial spondyloarthritis market. A detailed picture of the Axial spondyloarthritis pipeline landscape is provided, which includes the disease overview and Axial spondyloarthritis treatment guidelines.

Contact Info:

Kritika Rehani, Assistant Manager, Marketing & Branding
krehani@delveinsight.com
info@delveinsight.com
www.delveinsight.com
+14699457679

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

This release was published on openPR.